Skip to main content
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)Children's healthDrugPhase 2, Phase 3

What this study is

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).

What's being tested

  • Anakinra

    Intervention · DRUG

  • Placebo

    Intervention · DRUG

Both interventions

See information in arm/group descriptions

Study details

Official title
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS)
Sponsor
Nationwide Children's Hospital
Conditions
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Enrolling
500 people
Starts
2022-06-14
Est. completion
2028-08-31
Design
Quadruple-blind, randomized, parallel groups, Phase 2, Phase 3
Record
View on ClinicalTrials.gov ↗